Stock Worth Watching: Today Reata Pharmaceuticals Inc Stock Rises

Stock Worth Watching: Today Reata Pharmaceuticals Inc Stock Rises

The stock of Reata Pharmaceuticals Inc (NASDAQ:RETA) is a huge mover today! The stock increased 6.89% or $1.7 during the last trading session, hitting $26.36. About 162,739 shares traded hands or 9.35% up from the average. Reata Pharmaceuticals Inc (NASDAQ:RETA) has risen 6.00% since August 31, 2016 and is uptrending. It has underperformed by 4.42% the S&P500.
The move comes after 7 months positive chart setup for the $584.71 million company. It was reported on Sep, 30 by Barchart.com. We have $41.12 PT which if reached, will make NASDAQ:RETA worth $327.44 million more.

Analysts await Reata Pharmaceuticals Inc (RETA) to report earnings on November, 10. After $-0.05 actual EPS reported by Reata Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 60.00% negative EPS growth.

According to Zacks Investment Research, “Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States.”

More notable recent Reata Pharmaceuticals Inc (NASDAQ:RETA) news were published by: Marketwatch.com which released: “Reata Pharmaceuticals Inc. Cl A” on April 03, 2013, also Globenewswire.com with their article: “Reata Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering” published on May 26, 2016, Globenewswire.com published: “Reata Pharmaceuticals, Inc. Announces Second Quarter 2016 Financial and …” on August 11, 2016. More interesting news about Reata Pharmaceuticals Inc (NASDAQ:RETA) were released by: Globenewswire.com and their article: “Reata Pharmaceuticals, Inc. Announces Interim Data From Extension Phase 2 …” published on June 23, 2016 as well as Seekingalpha.com‘s news article titled: “We’re Cautious On The Reata Pharmaceuticals IPO” with publication date: May 25, 2016.

RETA Company Profile

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Firm is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates, bardoxolone methyl and RTA 408, are members of a class of small molecules called antioxidant inflammation modulators (AIMs).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment